Cargando…
The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series Study
Immunotherapy provided with checkpoint inhibitors such as the programmed cell death-1 (PD-1) receptor or its ligand-1 (PD-L1) protein has been shown to be effective for treating several types of cancer, and was recently approved for use in treating malignant melanoma, advanced non-small cell lung ca...
Autores principales: | Jin, Wei, Duan, Jian-Chun, Wang, Zhi-Jie, Lin, Lin, Bai, Hua, Wang, Jie, Feng, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654529/ https://www.ncbi.nlm.nih.gov/pubmed/33192094 http://dx.doi.org/10.2147/CMAR.S274830 |
Ejemplares similares
-
Vascular Thrombosis and Anti-PD-1 Therapy: A Series of Cases
por: Fu, Changfang, et al.
Publicado: (2021) -
Thymic tumours and their special features
por: Basse, Clémence, et al.
Publicado: (2021) -
Invasive atypical thymic carcinoid: three case reports and literature review
por: Zhu, Shan, et al.
Publicado: (2016) -
Tocilizumab for refractory morphea in adults: A case series
por: Lonowski, Sarah, et al.
Publicado: (2022) -
Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series
por: Zhang, Honghong, et al.
Publicado: (2017)